Co-Diagnostics Inc's fundamentals are relatively very healthy, and its growth potential is good.Its valuation is considered fairly valued, ranking 128/207 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 1.25.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Co-Diagnostics Inc's Score
Industry at a Glance
Industry Ranking
128 / 207
Overall Ranking
327 / 4563
Industry
Healthcare Equipment & Supplies
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
2
analysts
Buy
Current Rating
1.250
Target Price
+260.33%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Co-Diagnostics Inc Highlights
StrengthsRisks
Co-Diagnostics, Inc. is a molecular diagnostics company, which develops, manufactures and markets diagnostics technologies. The Company’s technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious disease. Its diagnostics systems enable dependable, low-cost, molecular testing for organisms and genetic diseases by automating or simplifying historically complex procedures in both the development and administration of tests. It is developing a portable diagnostic device and test system designed for point-of-care and at-home use. The system consists of its PCR instrument that it refers to as the Co-Dx PCR Pro instrument, its proprietary diagnostic test cup system and a mobile application to be installed on the user’s mobile device.
Growing
The company is in a growing phase, with the latest annual income totaling USD 3.92M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 3.92M.
Overvalued
The company’s latest PE is -0.24, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 11.14M shares, decreasing 2.69% quarter-over-quarter.
Co-Diagnostics, Inc. is a molecular diagnostics company, which develops, manufactures and markets diagnostics technologies. The Company’s technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious disease. Its diagnostics systems enable dependable, low-cost, molecular testing for organisms and genetic diseases by automating or simplifying historically complex procedures in both the development and administration of tests. It is developing a portable diagnostic device and test system designed for point-of-care and at-home use. The system consists of its PCR instrument that it refers to as the Co-Dx PCR Pro instrument, its proprietary diagnostic test cup system and a mobile application to be installed on the user’s mobile device.
Ticker SymbolCODX
CompanyCo-Diagnostics Inc
CEOEgan (Dwight H)
Websitehttps://codiagnostics.com/
FAQs
What is the current price of Co-Diagnostics Inc (CODX)?
The current price of Co-Diagnostics Inc (CODX) is 0.235.
What is the symbol of Co-Diagnostics Inc?
The ticker symbol of Co-Diagnostics Inc is CODX.
What is the 52-week high of Co-Diagnostics Inc?
The 52-week high of Co-Diagnostics Inc is 1.550.
What is the 52-week low of Co-Diagnostics Inc?
The 52-week low of Co-Diagnostics Inc is 0.228.
What is the market capitalization of Co-Diagnostics Inc?
The market capitalization of Co-Diagnostics Inc is 11.31M.
What is the net income of Co-Diagnostics Inc?
The net income of Co-Diagnostics Inc is -37.64M.
Is Co-Diagnostics Inc (CODX) currently rated as Buy, Hold, or Sell?
According to analysts, Co-Diagnostics Inc (CODX) has an overall rating of Buy, with a price target of 1.250.
What is the Earnings Per Share (EPS TTM) of Co-Diagnostics Inc (CODX)?
The Earnings Per Share (EPS TTM) of Co-Diagnostics Inc (CODX) is -0.974.